Dark

Check out our Dark Pool Levels

DERM
Journey Medical Corporation Common Stock
stock NASDAQ

Market Open

Aug 6, 2026 1:02:03 PM EDT

6.49USD+1.248%(+0.08)51,592

6.48Bid 7.34Ask 0.86Spread

Pre-market

Aug 5, 2026 8:48:30 AM EDT

6.52USD+1.875%(+0.12)0

After-hours

Aug 4, 2026 4:00:30 PM EDT

6.40USD-0.467%(-0.03)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 13, 2022

11:45AM EST VYNE Therapeutics Divests Topical Minocycline Assets; Transaction Includes Cash Payments Of $25M And Potential Milestones Of Up To $450M Benzinga

07:00AM EST Transaction includes cash payments of $25 million and potential milestones of up to $450 million GlobeNewswire Inc

07:00AM EST Franchise includes AMZEEQ for the treatment of acne and ZILXI for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform GlobeNewswire Inc

Dec 16, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 Benzinga

06:56AM EST Roth Capital Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $15 Benzinga

Dec 10, 2021

08:03AM EST Journey Medical Q3 EPS $0.32 Up From $0.06 YoY, Sales $19.60M Up From $9.40M YoY Benzinga

08:00AM EST Generated record net revenues of $19.6 million for the third quarter of 2021 GlobeNewswire Inc

Dec 9, 2021

09:52PM EST From Benzinga's Global Small Cap Conference: Journey Medical President & CEO, Claude Maraoui & CFO Ernest De Paolantonio Begins Presenting Benzinga

Dec 7, 2021

04:05PM EST Journey Medical Corporation (Journey Medical) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 9, 2021. GlobeNewswire Inc

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 Benzinga

06:10AM EST B. Riley Securities Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $14 Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 29, 2021

08:00AM EST Journey Medical Corporation Introduces Expanded Board of Directors GlobeNewswire Inc

Nov 16, 2021

04:01PM EST Journey Medical Corporation Announces Closing of Initial Public GlobeNewswire Inc

Nov 12, 2021

07:25AM EST Fortress Bio Subsidiary Journey Medical Prices IPO Of 3.52M Shares Benzinga

07:00AM EST Journey Medical Corporation (NASDAQ: DERM) (Journey Medical), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress), today announced the pricing of its initial public offering of common stock. GlobeNewswire Inc

Nov 8, 2021

10:13AM EST Journey Medical Corporation Announces Launch of its Initial Public GlobeNewswire Inc

Apr 1, 2021

07:15AM EDT Journey Medical To Acquire QBREXZA In The U.S. From Dermira RTTNews

Share